TITLE

CAMBRIDGE ANTIBODY TECHNOLOGY/AMGEN RESTRUCTURE AGREEMENT

PUB. DATE
February 2004
SOURCE
Worldwide Biotech;Feb2004, Vol. 16 Issue 2, p8
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
Announces the restructuring of an antibody development and marketing collaboration agreement of Cambridge Antibody Technology Group plc Immunex Corporation.
ACCESSION #
12067825

 

Related Articles

  • CAT's phage technology patent upheld. Hodgson, John // Nature Biotechnology;Aug2000, Vol. 18 Issue 8, p809 

    Reports that the opposition division of the European Patent Office has upheld Cambridge Antibody Technology Ltd.'s European patent without amendments following a challenge from Dyax Corp. and Morphosys AG. Reasons to upheld the European paten.

  • Making Monoclonals Human. Sellers, L. J. // Pharmaceutical Executive;Jul2000, Vol. 20 Issue 7, p96 

    Interviews David Chiswell, founding chief executive officer of the Cambridge Antibody Technology (CAT). Background information on the company; Comparison between the fully human antibodies developed with others in the market; Details on the unique antibody isolation technology CAT has...

  • Patent case unblocks antibody businesses. Hodgson, John // Nature Biotechnology;Dec99, Vol. 17 Issue 12, p1154 

    Presents details about a patent dispute between the two companies Cambridge Antibody Technology Ltd. and MorphoSys AG. Reason for the opposition of the patent by MorphoSys; Factors due to which the controversy might take considerable amount of time to get resolved; Allegations on MorphoSys AG...

  • CAT and Abbott Dispute Humira Royalties.  // Pharmaceutical Executive;Dec2003, Vol. 23 Issue 12, p32 

    Reports that Cambridge Antibody Technology Group PLC has received its first royalty payment from Abbott Laboratories. Terms of the license agreement for monoclonal antibody arthritis treatment.

  • Cambridge Antibody Technology plc: Interim results for the six months ended 31st March, 2004. Aaronson, Colin // Journal of Commercial Biotechnology;Oct2004, Vol. 11 Issue 1, p97 

    The article presents information related to Cambridge Antibody Technology Group PLC (CAT). CAT has established itself as a leader in the development of human monoclonal antibodies as new treatments for disease, based upon its own antibody technology. One of its drugs is used for the treatment...

  • Herbert Smith lands major biotech client. Malkin, Brendan // Lawyer;12/1/2003, Vol. 17 Issue 47, p10 

    Reports that Cambridge Antibody Technology has hired the law firm Herbert Smith in a major litigation. Exclusion of law firm Mayer Brown Rowe & Maw in a competitive bidding to represent the firm; Case against Abbott Laboratories Inc.; Disagreement over royalty payments.

  • Products. Smith, Davis N. // Pharmaceutical Executive;Mar2001, Vol. 21 Issue 3, p133 

    Focuses on the research partnerships and collaborations in the pharmaceutical industry as of March 2001. Terms of the strategic partnership between Elan and Cambridge Antibody Technology to develop novel therapeutics to treat neurological disorders; Program of Incyte Genomics and Oxagen...

  • European Biotech Begins to Merge. Houlton, Sarah // Pharmaceutical Executive;Mar2003, Vol. 23 Issue 3, p22 

    Reports that Cambridge Antibody Technology is buying Oxford GlycoSciences (OGS). Equivalent shares of OGS shareholders.

  • Rivals Vie for Cash-Rich OGS. Houlton, Sarah // Pharmaceutical Executive;Apr2003, Vol. 23 Issue 4, p18 

    Reports on the impediment to the all-share acquisition of drug company Oxford GlycoSciences by Cambridge Antibody Technology after CellTech's presentation of an intention to bid. Rejection of bid by Oxford Glycosciences' management.

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics